drugset / Trial / NCT01971346

The Immunological Basis for Treatment Resistance to Anti-TNF Treatments

NCT01971346

Phase 4 Completed 50 enrolled University of Michigan Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the relationship between two types of cell signals, type I interferon (IFN) and tumor necrosis factor (TNF), in psoriatic skin prior to and during treatment with etanercept and correlate that information with the degree of the improvement in the psoriasis.

Timeline

Start
2014-03-13
Primary completion
2017-11-01
Completion
2017-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 100 mg Subcutaneous

Indications